Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, Nakanishi R, Yasumoto K
Department of Surgery II, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.
Surg Oncol. 1995;4(2):83-9. doi: 10.1016/s0960-7404(10)80011-8.
We examined proliferating cell nuclear antigen (PCNA) in 102 patients with surgically treated non-small cell lung cancer (NSCLC). PCNA labelling index (LI) tended to be higher in tumours of higher stages than those of early stages, in squamous cell carcinomas than adenocarcinomas, or in poorly differentiated adenocarcinoma than in well-differentiated. A positive correlation was observed between the PCNA LI and argyrophilic nucleolar organizer regions (Ag-NOR) count which we previously examined (r = 0.31, P = 0.002). In survival analysis of 79 patients who died of lung cancer, only age, stage and PCNA LI were found to be significant prognostic factors on multivariate analysis among seven potential prognostic factors including sex, age, year of operation, histological type, stage, Ag-NOR count, and PCNA LI. We conclude that PCNA may be superior to Ag-NOR in predicting shortened survival of patients with non-small cell lung cancer. PCNA staining can be performed with ease and it may be applied in a clinical laboratory on a routine basis to help predict prognosis of NSCLC.
我们对102例接受手术治疗的非小细胞肺癌（NSCLC）患者的增殖细胞核抗原（PCNA）进行了检测。PCNA标记指数（LI）在晚期肿瘤中往往高于早期肿瘤，在鳞状细胞癌中高于腺癌，或在低分化腺癌中高于高分化腺癌。PCNA LI与我们之前检测的嗜银核仁组织区（Ag-NOR）计数之间存在正相关（r = 0.31，P = 0.002）。在79例死于肺癌的患者的生存分析中，在包括性别、年龄、手术年份、组织学类型、分期、Ag-NOR计数和PCNA LI在内的七个潜在预后因素中，多因素分析发现只有年龄、分期和PCNA LI是显著的预后因素。我们得出结论，在预测非小细胞肺癌患者生存期缩短方面，PCNA可能优于Ag-NOR。PCNA染色操作简便，可在临床实验室常规应用以帮助预测NSCLC的预后。
